Rein Therapeutics (RNTX) Total Liabilities (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Total Liabilities of $14.7 million for Q1 2026, up 89.66% year-over-year from $7.7 million in Q1 2025, and up 103.0% quarter-over-quarter from $7.2 million in Q4 2025.
Rein Therapeutics (RNTX) Total Liabilities (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Total Liabilities for 11 consecutive years, with $14.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 89.66% year-over-year to $14.7 million; the TTM figure through Mar 2026 stood at $14.7 million (up 89.66% YoY), while the FY2025 annual figure was $7.2 million, down 7.16% from the prior year.
- Total Liabilities rose to $14.7 million in Q1 2026 per RNTX's latest filing, from $7.2 million in the prior quarter.
- Across five years, Total Liabilities topped out at $14.7 million in Q1 2026 and bottomed at $1.2 million in Q2 2023.
- Historically, Total Liabilities has averaged $6.5 million across 5 years, with a median of $7.5 million in 2025.
- Annual changes were most pronounced in 2023 — Total Liabilities tumbled 76.76% — and 2024, when it jumped 600.0%.
- Rein Therapeutics' Total Liabilities stood at $3.4 million in 2022, then jumped by 127.87% to $7.7 million in 2023, then gained by 1.13% to $7.8 million in 2024, then retreated by 7.16% to $7.2 million in 2025, then surged by 103.0% to $14.7 million in 2026.
- Business Quant data shows RNTX's Total Liabilities at $14.7 million in Q1 2026, $7.2 million in Q4 2025, and $7.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | 10.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.77 Mn |
| Mar 31, 2026 | 14.70 Mn |
| Dec 31, 2025 | 7.24 Mn |
| Sep 30, 2025 | 7.52 Mn |
| Jun 30, 2025 | 9.47 Mn |
| Mar 31, 2025 | 7.75 Mn |
| Dec 31, 2024 | 7.80 Mn |
| Sep 30, 2024 | 8.99 Mn |
| Jun 30, 2024 | 8.38 Mn |
| Mar 31, 2024 | 7.86 Mn |
| Dec 31, 2023 | 7.71 Mn |
| Sep 30, 2023 | 1.62 Mn |
| Jun 30, 2023 | 1.20 Mn |
| Mar 31, 2023 | 2.88 Mn |
| Dec 31, 2022 | 3.38 Mn |
| Sep 30, 2022 | 4.54 Mn |
| Jun 30, 2022 | 5.15 Mn |
| Mar 31, 2022 | 4.15 Mn |
| Dec 31, 2021 | 4.58 Mn |
| Sep 30, 2021 | 4.66 Mn |